This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Publication Indicates That MultiStem Treatment May Reduce Inflammation And Promote Reparative Processes Following Acute Brain Injury

Stocks in this article: ATHX

CLEVELAND, Oct. 10, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today the publication of an article in the peer-reviewed scientific journal, Journal of Neuroinflammation, that describes the results of a preclinical study evaluating the administration of MultiStem ® cell therapy for the treatment of traumatic brain injury (TBI) in rodents. The article, authored by investigators from The University of Texas Health Science Center at Houston (UTHealth), together with scientists from Athersys, describes preclinical study results demonstrating that administration of MultiStem cells modulates the inflammatory environment that follows TBI, by reducing immune cell and cytokine activity associated with inflammation.

TBI affects approximately 1.7 million patients in the United States annually and severe injuries can be associated with significant long-term physical, cognitive and psychological deficits.  As in other acute injuries and diseases affecting the central nervous system, such as stroke and spinal cord injury, TBI leads to substantial inflammation, which slows innate recovery processes and contributes to secondary tissue damage.

The publication further illustrates the mechanisms through which cellular therapy may provide benefit to patients suffering significant injury to the central nervous system. "MultiStem therapy shows promise for treating traumatic brain injury, as well as ischemic stroke and spinal cord injury," said Dr. Robert Mays, Head of Neuroscience at Athersys.  "These latest preclinical results further confirm that MultiStem cells have substantial anti-inflammatory and immunomodulatory properties that could be important in treating multiple central nervous system disease conditions."

In pre-clinical experiments, rodents underwent controlled cortical impact brain injury receiving either MultiStem cells or placebo following the injury. The injured, cell-treated animals had significant increases in T-regulatory cells in the spleen and plasma at 24 and 48 hours, respectively, compared to the placebo-treated animals. Further, MultiStem treatment was associated with an increase in the ratio of neuroprotective (M2) macrophages relative to proinflammatory (M1) macrophages responsible for the production of inflammatory cytokines and associated neurotoxicity.  Additionally, cell treatment resulted in a reduction of blood brain barrier permeability and preserved splenic mass following the injury, suggesting that MultiStem treatment may provide benefit to TBI patients through multiple pathways.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs